| 2024-05-17 |
6-K |
CURRENT REPORT |
View Document |
| 2024-05-17 |
6-K |
GSK COMPLETES SALE OF SHARES IN HALEON PLC |
View Document |
| 2024-05-14 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-05-13 |
6-K |
BLOCK LISTING INTERIM REVIEW |
View Document |
| 2024-05-08 |
6-K |
RESULT OF AGM |
View Document |
| 2024-05-08 |
6-K |
BOARD COMMITTEE CHANGE |
View Document |
| 2024-05-03 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-05-01 |
6-K |
1ST QUARTER RESULTS |
View Document |
| 2024-05-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-04-24 |
6-K |
US FDA ACCEPTS NEW INDICATION FILING FOR JEMPERLI |
View Document |
| 2024-04-19 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-04-17 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-04-17 |
6-K |
RESULTS FROM LONG-TERM DATA RELATING TO SHINGRIX |
View Document |
| 2024-04-17 |
6-K |
GSK ANNOUNCES ADDITIONAL EAGLE-1 RESULTS |
View Document |
| 2024-04-16 |
6-K |
AMENDMENT - DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-04-16 |
6-K |
FDA ACCEPTS GSK MENINGITIS VACCINE CANDIDATE FILE |
View Document |
| 2024-04-15 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-04-04 |
6-K/A |
REPLACEMENT - TOTAL VOTING RIGHTS |
View Document |
| 2024-04-02 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-03-28 |
SC 13D/A |
AMENDMENT TO FORM SC 13D |
View Document |
| 2024-03-26 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-03-25 |
F-3ASR |
F-3ASR |
View Document |
| 2024-03-25 |
6-K |
NOTICE OF AGM |
View Document |
| 2024-03-22 |
6-K |
TRANSFER OF TREASURY SHARES |
View Document |
| 2024-03-22 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-03-18 |
6-K |
NEW PHASE III JEMPERLI DATA IN ENDOMETRIAL CANCER |
View Document |
| 2024-03-13 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-03-08 |
6-K |
BOARD COMMITTEE CHANGE |
View Document |
| 2024-03-07 |
6-K |
GSK ANNOUNCES POSITIVE BLENREP DREAMM-8 RESULTS |
View Document |
| 2024-03-06 |
6-K |
VIIV LAI VS ORAL SOC DATA IN ADHERENCE-CHALLENGED |
View Document |
| 2024-03-05 |
6-K |
GSK ANNUAL REPORT 2023 ON FORM 20 F |
View Document |
| 2024-03-05 |
IRANNOTICE |
IRANNOTICE |
View Document |
| 2024-03-05 |
20-F |
20-F |
View Document |
| 2024-03-05 |
6-K |
NEW VIIV LA FORMULATION POTENTIAL 4-MONTH DOSING |
View Document |
| 2024-03-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-03-01 |
6-K |
GSK PUBLISHES ANNUAL REPORT 2023 |
View Document |
| 2024-02-29 |
6-K |
DIRECTORATE CHANGE |
View Document |
| 2024-02-29 |
6-K |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
View Document |
| 2024-02-26 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-02-26 |
6-K |
GSK ANNOUNCES POSITIVE EAGLE-1 HEADLINE RESULTS |
View Document |
| 2024-02-22 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-02-21 |
6-K |
VIIV LAI SUPERIOR TO ORALS IN ADHERENCE-CHALLENGED |
View Document |
| 2024-02-20 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-02-15 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-02-15 |
6-K |
GSK COMPLETES ACQUISITION OF AIOLOS BIO |
View Document |
| 2024-02-13 |
SC 13G/A |
SC 13G/A |
View Document |
| 2024-02-13 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-02-13 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-02-13 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-02-12 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-02-12 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-02-12 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-02-12 |
6-K |
US FDA FAST TRACK DESIGNATION FOR BEPIROVIRSEN |
View Document |
| 2024-02-09 |
SC 13D/A |
AMENDMENT TO SC 13D |
View Document |
| 2024-02-06 |
SC 13G/A |
AMENDMENT TO FORM SC 13G |
View Document |
| 2024-02-06 |
SC 13G/A |
AMENDMENT TO FORM SC 13G |
View Document |
| 2024-02-06 |
6-K |
FDA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK |
View Document |
| 2024-02-06 |
6-K |
SHINGRIX 18+ AT RISK CHINA FILING REVIEW ACCEPTED |
View Document |
| 2024-02-06 |
6-K |
GSK PRESENTS POSITIVE DREAMM-7 PHASE III DATA |
View Document |
| 2024-02-01 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-02-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2024-02-01 |
6-K |
STATEMENT: ZANTAC (RANITIDINE) LITIGATION |
View Document |
| 2024-01-31 |
6-K |
FINAL RESULTS |
View Document |
| 2024-01-30 |
4 |
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP |
View Document |
| 2024-01-29 |
6-K |
EMA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK |
View Document |
| 2024-01-29 |
6-K |
EUROPEAN COMMISSION AUTHORISES OMJJARA IN THE EU |
View Document |
| 2024-01-19 |
SC 13D/A |
AMENDMENT TO FORM SC 13D |
View Document |
| 2024-01-19 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-01-17 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-01-17 |
6-K |
CURRENT REPORT |
View Document |
| 2024-01-17 |
6-K |
GSK COMPLETES SALE OF SHARES IN HALEON PLC |
View Document |
| 2024-01-16 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2024-01-10 |
6-K |
NUCALA APPROVED IN CHINA FOR USE IN SEVERE ASTHMA |
View Document |
| 2024-01-09 |
6-K |
GSK ENTERS AGREEMENT TO ACQUIRE AIOLOS BIO |
View Document |
| 2024-01-02 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2023-12-21 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2023-12-18 |
6-K |
JEMPERLI PLUS ZEJULA TRIAL MEETS ENDPOINT |
View Document |
| 2023-12-13 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2023-12-12 |
6-K |
JAPAN ACCEPTS AREXVY FILING FOR AT RISK ADULTS |
View Document |
| 2023-12-11 |
6-K |
JEMPERLI PLUS CHEMOTHERAPY EU AUTHORISATION |
View Document |
| 2023-12-04 |
6-K |
GSK PUBLISHES PROVISIONAL 2024 DIVIDEND DATES |
View Document |
| 2023-12-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2023-11-30 |
6-K |
BLOCK LISTING APPLICATION |
View Document |
| 2023-11-29 |
6-K |
HOLDING(S) IN COMPANY |
View Document |
| 2023-11-27 |
6-K |
GSK ANNOUNCES POSITIVE DREAMM-7 HEADLINE RESULTS |
View Document |
| 2023-11-21 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2023-11-15 |
6-K |
BLOCK LISTING INTERIM REVIEW |
View Document |
| 2023-11-13 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2023-11-13 |
6-K |
GSK RECEIVES POSITIVE CHMP OPINION FOR MOMELOTINIB |
View Document |
| 2023-11-01 |
6-K |
TOTAL VOTING RIGHTS |
View Document |
| 2023-11-01 |
6-K |
3RD QUARTER RESULTS |
View Document |
| 2023-10-30 |
6-K |
JEMPERLI TRIAL MEETS OVERALL SURVIVAL ENDPOINT |
View Document |
| 2023-10-26 |
6-K |
NMPA APPROVES VOCABRIA+REKAMBYS IN CHINA |
View Document |
| 2023-10-25 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2023-10-25 |
6-K |
NEW DATA FOR AREXVY, GSK'S RSV VACCINE |
View Document |
| 2023-10-20 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2023-10-18 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2023-10-17 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
| 2023-10-16 |
6-K |
JEMPERLI PLUS CHEMOTHERAPY POSITIVE CHMP OPINION |
View Document |
| 2023-10-13 |
6-K |
DIRECTOR/PDMR SHAREHOLDING |
View Document |
